Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $86.00 at JMP Securities

Structure Therapeutics (NASDAQ:GPCR) had its target price decreased by JMP Securities from $91.00 to $86.00 in a research note released on Friday, Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

GPCR has been the topic of several other reports. JPMorgan Chase & Co. assumed coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an overweight rating and a $65.00 price target on the stock. BMO Capital Markets increased their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research note on Friday, June 7th. Finally, Cantor Fitzgerald restated an overweight rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, July 1st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and an average price target of $84.63.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded down $0.72 during trading hours on Friday, reaching $33.77. 769,472 shares of the stock were exchanged, compared to its average volume of 820,716. The stock has a market cap of $1.57 billion, a P/E ratio of -43.86 and a beta of -3.52. Structure Therapeutics has a 52-week low of $25.57 and a 52-week high of $75.02. The firm’s 50 day moving average is $42.13 and its 200 day moving average is $40.74.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Equities research analysts expect that Structure Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors have recently modified their holdings of the business. Brandywine Managers LLC increased its position in shares of Structure Therapeutics by 9.2% during the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after purchasing an additional 1,007 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its position in shares of Structure Therapeutics by 17.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after acquiring an additional 2,077 shares during the period. Sectoral Asset Management Inc. acquired a new position in Structure Therapeutics during the fourth quarter worth approximately $139,000. TrueMark Investments LLC raised its stake in Structure Therapeutics by 13.5% in the first quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after buying an additional 3,562 shares during the period. Finally, Pier Capital LLC raised its stake in Structure Therapeutics by 3.7% in the second quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock valued at $3,974,000 after buying an additional 3,647 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.